Quick Search (by title or disease)
  

Go to Advanced Search for more options.

Clinical Trials Help

Contact our Cancer Information Line nurse with your questions about open or upcoming clinical trials, second opinions, or patient referrals.
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

Breast cancer Clinical Trials

Protocol Number Title
2009NTLS011
Tobacco-related Biomarkers in Head and Neck Squamous Cell Carcinoma; Tobacco-Related Biomarkers for Risk Assessment and Prognosis in the Development and Treatment of Head and Neck Squamous Cell Carcinoma; Tobacco carcinogens as markers of exposure, carcinogenesis and risk in oral cancer.
2009NTLS059
Methodology and Development of Tobacco Related Biomarkers Methodology and Development of Tobacco Related Biomarkers, part of 'Metabolism of Carcinogenic Tobacco-Specific Nitrosamines'
2009UC147
Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis (ISPY2)
2009UC147SS
2009UC147: SURMOUNT: Surveillance Markers of Utility for Recurrence after Neoadjuvant Therapy for Breast Cancer (Supplement 3 Sub-study to ISPY2)
2011NTLS154
Benzo[a]pyrene Metabolism: Phenotyping and Genotyping Study 4: Deuterated Phenanthrene and NNK Cigarettes
2013NTLS035
Vascular Assessment in Breast Cancer Survivors Taking Aromatase Inhibitors
2013NTLS041
A Device to Quantify Sweat of Single Sweat Glands to Diagnose Neuropathy
2013NTLS123
Quantitative Methods for Supplementing Contrast-Enhanced Magnetic Resonance Imaging of Breast Cancer.
2014IS044
Millenium C31001: A phase 1b/2 study of safety and efficacy of MLN0128 (Dual TORC 1/2 Inhibitor) in combination with exemestane or fulvestrant therapy in postmenopausal women with ER+/HER2- advanced or metastatic breast cancer that has progressed on treatment with everolimus in combination with exemestane or fulvestrant
2014IS090
APS001F-001 ? A Phase I/II safety, pharmacokinetic, and pharmacodynamic study of APS001F with flucytosine and maltose for the treatment of advanced and/or metastatic solid tumors.
2014NTLS052
Pilot Study of Clone 6 scFv As a Novel Marker for Isolation and Characterization of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer and Bladder Cancer
2015IS087
A Phase I, First-Time-in-Human Study of MEDI9197, a TLR 7/8 Agonist, Administered Intratumorally in Subjects with a Solid Tumor Cancer
2015IS111
An Open-Label, Multicenter, Global Phase II Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
2015IS182
Phase 2 Randomized, Double-Blinded, Controlled Study of ONT-380 vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
2015NTLS004
Measurement of Local Tissue Water
2015NTLS026
Aromatase Inhibitors and Vascular Health
2015NTLS139
Changes in Biomarkers Associated with Use of Electronic Cigarettes among African American Menthol and Nonmenthol Smokers
2016IS065
An open label, phase Ib, dose-escalation study evaluating the safety and tolerability of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumours and in combination with endocrine therapy in patients with locally advanced or metastatic hormone receptor-positive, HER2-, breast cancer, followed by expansion cohorts
2016IS069
A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects with Advanced Malignancies
2016IS106
An Open-Label Phase 2 Study of MLN0128 (A TORC1/2 Inhibitor) in Combination With Fulvestrant in Women With ER-Positive/HER2-Negative Advanced or Metastatic Breast Cancer That Has Progressed During or After Aromatase Inhibitor Therapy.
2016IS173
A phase 3 open label, randomized, multicenter study of NKTR-102 versus treatment of physician's choice (TPC) in patients with metastatic breast cancer who have stable brain metastases and have been previously treated with an anthracycline, a taxan, and capectabine
2016IS192
A Phase 1, Open-Label, Multicenter, Dose escalation study of mRNA-2416, a lipid nanoparticle encapsulated mRNA encoding human OX40L, for intratumoral injection to patients with advanced malignancies
2016UC078
A Single Arm Phase II Study of Palbociclib in Combination with Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer: Big Ten Cancer Research Consortium BTCRC-BRE15-016
2017IS028
Phase I Trial of Intratumoral Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and human interferon beta (VSV-IFNβ-NIS), in Patients with Refractory Solid Tumors
EAY131-Z1C
EAY131-Z1C: MATCH Treatment Subprotocol Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC
EAY131-Z1I
EAY131-Z1I: MATCH Treatment Subprotocol Z1I: Phase II Study of AZD1775 in Patients with Tumors Containing BRCA1 and BRCA2 Mutations
PEDS-2016-25172
Collaborative Perinatal Project Minnesota Cohort Follow-up Study (CPP-MN 2.0)

27 trials displayed